Pharmafile Logo
Pharmafocus logo
Advanced Search

CSL Behring

Showing 5 posts of 5 posts found.

hsm_mobile_clinical_trial_istock-872676342

CSL Behring’s angioedema treatments receives NICE recommendation

September 26, 2025
Regulatory Affairs, Research and Development Andembry, CSL Behring, hereditary angioedema

The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending CSL Behring’s ANDEMBRY (garadacimab) for …

News

CSL Behring’s therapy for hereditary angioedema receives positive assessment in Germany

June 26, 2025
Market Access, Market Research, Medical Communications, Research and Development, Sales and Marketing CSL Behring, Institute for Quality and Efficiency in Health Care, Rare Diseases, clinical trials, hereditary angioedema, market access

CSL Behring has announced a key milestone for its hereditary angioedema (HAE) therapy, garadacimab, following a positive benefit assessment by …

News

First UK patient treated with CSL Behring’s gene therapy for Haemophilia B

June 20, 2025
Research and Development CSL Behring, Haematology, NHS England, cell therapy, gene therapy, haemophilia B, prophylactic infusions

CSL Behring has announced that the first patient in the UK has received HEMGENIX (etranacogene dezaparvovec) through the NHS, marking …

News
csl_behring

FDA approves CSL Behring’s new haemophilia B treatment

March 7, 2016
Research and Development, Sales and Marketing CSL Behring, haemophilia

The US Food and Drug Administration (FDA) has approved CSL Behring’s Idelvion (Coagulation Factor IX (Recombinant)), a novel, long-acting albumin …

News
CSL Behring

CSL Behring launches new dosing app

June 27, 2012
Medical Communications Beriplex P/N, CSL Behring, app, digital

Biotherapy firm CSL Behring UK has launched an app for doctors to aid the management of its anaesthetic treatment Beriplex …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025